Tazobactam






122 Article(s)
Download
PMID
Title
Journal
Pub. Date
#Total Relationship(s)
1 1652728 [In vitro synergistic activity of piperacillin-tazobactam combination against beta-lactam antibiotics resistant strains of Enterobacteriaceae]. Pathol Biol (Paris) 1991 May 1
2 1661596 Beta-lactamase inhibitors: relation between kinetic data and in-vitro synergism studies. Zentralbl Bakteriol 1991 Oct 1
3 1685175 Antimicrobial activities of piperacillin alone and in combination with tazobactam against beta-lactamase-producing bacteria. J Formos Med Assoc 1991 Oct 5
4 1965317 Comparative in-vitro activity of piperacillin and piperacillin plus tazobactam towards beta-lactamase producing clinical isolates. J Chemother 1990 Oct 3
5 2127343 Beta-lactam-fosfomycin antagonism involving modification of penicillin-binding protein 3 in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1990 Nov 1
6 2558615 Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Antimicrob Agents Chemother 1989 Nov 1
7 3039137 Synthesis and beta-lactamase inhibitory properties of 2 beta-[(1,2,3-triazol-1-yl)methyl]-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide and related triazolyl derivatives. J Med Chem 1987 Aug 1
8 7607408 Outer membrane permeability of beta-lactamase inhibitors in Pseudomonas aeruginosa. FEMS Microbiol Lett 1995 Jun 15 1
9 7640670 A piperacillin-tazobactam resistant Escherichia coli strain isolated from a faecal sample of a healthy volunteer. FEMS Immunol Med Microbiol 1995 Apr 1
10 7675548 [In vitro antibacterial activity of piperacillin-tazobactam in combination with netilmicin or amikacin against Enterobacteriaceae resistant to amoxicillin]. Pathol Biol (Paris) 1995 Mar 1
11 7752448 [Comprehensive evaluation of pharmacokinetic and clinical studies on tazobactam/piperacillin in pediatric field]. Jpn J Antibiot 1995 Mar 1
12 7752449 [Bacteriological and clinical evaluation tazobactam/piperacillin in infectious diseases in surgical field]. Jpn J Antibiot 1995 Mar 1
13 8040112 beta-Lactamase types amongst Staphylococcus aureus isolates in relation to susceptibility to beta-lactamase inhibitor combinations. J Antimicrob Chemother 1994 Mar 2
14 8141570 Comparative activities of piperacillin and tazobactam against clinical isolates of Legionella spp. Antimicrob Agents Chemother 1994 Jan 1
15 8226427 Multicentre survey of the comparative in-vitro activity of piperacillin/tazobactam against bacteria from hospitalized patients in the British Isles. J Antimicrob Chemother 1993 Aug 2
16 8257123 Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli. Antimicrob Agents Chemother 1993 Oct 2
17 8262865 Behaviour of beta-lactamase-positive and -negative Staphylococcus aureus isolates in susceptibility tests with piperacillin/tazobactam and other beta-lactam/beta-lactamase inhibitor combinations. J Antimicrob Chemother 1993 Sep 2
18 8383653 Susceptibility survey of piperacillin alone and in the presence of tazobactam. J Antimicrob Chemother 1993 Jan 1
19 8388201 Kinetic interactions of tazobactam with beta-lactamases from all major structural classes. Antimicrob Agents Chemother 1993 Apr 7
20 8392995 Selection of variants of the TEM-1 beta-lactamase, encoded by a plasmid of clinical origin, with increased resistance to beta-lactamase inhibitors. J Antimicrob Chemother 1993 May 1
21 9044033 pH effects on the inhibition of extended-spectrum and classical TEM beta-lactamases by penicillanic acid sulphones. J Antimicrob Chemother 1997 Jan 1
22 9053535 [Clinical study of tazobactam/piperacillin in obstetrics and gynecological infections]. Jpn J Antibiot 1996 Aug 1
23 9186563 SYN-1012: a new beta-lactamase inhibitor of penem skeleton. J Antibiot (Tokyo) 1997 Apr 2
24 9505187 Tolerability of piperacillin/tazobactam in children and adolescents after high dose radio-/chemotherapy and autologous stem cell transplantation. Infection 1998 Jan-Feb 2
25 9527373 [Characterization of the resistance to combinations of beta lactams and inhibitors of beta-lactamases in Escherichia coli. Effect of the type and amount of beta-lactamase production]. Enferm Infecc Microbiol Clin 1997 Nov 1
26 9693964 [Clinical studies of tazobactam/piperacillin (TAZ/PIPC) in pediatric patients]. Jpn J Antibiot 1998 May 3
27 9693965 [Clinical studies on tazobactam/piperacillin (YP-14) in the pediatric field]. Jpn J Antibiot 1998 May 1
28 9693967 [Pharmacokinetic, bacteriological and clinical evaluation of tazobactam/piperacillin in pediatrics]. Jpn J Antibiot 1998 May 1
29 9755832 [Transferability of tazobactam/piperacillin (TAZ/PIPC) to cerebrospinal fluid of rabbit with meningitis caused by Staphylococcus aureus]. Jpn J Antibiot 1998 Jun 2
30 10331993 Inhibitor resistant class A beta-lactamases. Front Biosci 1999 May 15 1
31 10350372 Inhibitor-resistant TEM beta-lactamases: phenotypic, genetic and biochemical characteristics. J Antimicrob Chemother 1999 Apr 1
32 10423234 X-ray structure of the Asn276Asp variant of the Escherichia coli TEM-1 beta-lactamase: direct observation of electrostatic modulation in resistance to inactivation by clavulanic acid. Biochemistry 1999 Jul 27 1
33 10678785 Antimicrobial chemotherapy in the control of surgical infectious complications. J Chemother 1999 Dec 1
34 10837472 Mechanism of inhibition of the class A beta -lactamases PC1 and TEM-1 by tazobactam. Observation of reaction products by electrospray ionization mass spectrometry. J Biol Chem 2000 Sep 1 11
35 11036023 A novel class A extended-spectrum beta-lactamase (BES-1) in Serratia marcescens isolated in Brazil. Antimicrob Agents Chemother 2000 Nov 1
36 11305007 [Antibiotics--TAZ/PIPC, synercid, linezolid, everninomicin]. Nihon Rinsho 2001 Apr 1
37 11327849 Inhibition of the SHV-1 beta-lactamase by sulfones: crystallographic observation of two reaction intermediates with tazobactam. Biochemistry 2001 Feb 13 1
38 11412645 [Comparative study of piperacillin/tazobactam versus imipenem/cilastatin in febrile neutropenia (1994-1996)]. Med Clin (Barc) 2001 May 5 2
39 11758235 [Clinical analysis of nosocomial infection of extended spectrum beta-lactamase-producing bacteria]. Zhonghua Nei Ke Za Zhi 2001 Sep 3
40 14534312 Understanding resistance to beta-lactams and beta-lactamase inhibitors in the SHV beta-lactamase: lessons from the mutagenesis of SER-130. J Biol Chem 2003 Dec 26 1
41 14638498 Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing beta-lactamase KPC-2. Antimicrob Agents Chemother 2003 Dec 1
42 15518561 Inhibitor-resistant class A beta-lactamases: consequences of the Ser130-to-Gly mutation seen in Apo and tazobactam structures of the SHV-1 variant. Biochemistry 2004 Nov 9 1
43 15647409 Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration. J Clin Pharmacol 2005 Feb 1
44 16248372 [Clinical effects of piperacillin and tazobactam/piperacillin on Haemophilus influenzae lower respiratory tract infection in pediatric patients]. Kansenshogaku Zasshi 2005 Sep 1
45 17017804 Rational design of a beta-lactamase inhibitor achieved via stabilization of the trans-enamine intermediate: 1.28 A crystal structure of wt SHV-1 complex with a penam sulfone. J Am Chem Soc 2006 Oct 11 1
46 18059098 Prevalence and antimicrobial susceptibility pattern of extended-spectrum beta-lactamase-producing Enterobacteriaceae in the United Arab Emirates. Med Princ Pract 2008 3
47 18068869 Tachyplesin III and granulocyte-colony stimulating factor enhance the efficacy of tazobactam/piperacillin in a neutropenic mouse model of polymicrobial peritonitis. Peptides 2008 Jan 1
48 18509771 Isolation of the first metallo-beta-lactamase producing Klebsiella pneumoniae in Lebanon. Rev Esp Quimioter 2008 Jun 2
49 18559643 Inhibition of OXA-1 beta-lactamase by penems. Antimicrob Agents Chemother 2008 Sep 1
50 18611801 In vitro comparative assessment of beta-lactamase inhibitors and their penicillin combinations against selected enterobacteria. Int J Antimicrob Agents 1997 1